Skip to content

Latha Velayudhan

King's College London

2 papers in the library · 16 citations · publishing 2024-2025

Papers

Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases

Pharmacology & Therapeutics April 6, 2024 Zarah R. Haniff, Mariia Bocharova, Tim Mantingh et al. 16 citations

Major depression increases the risk of later dementia, and late-life depression may be an early sign of dementia. Adult hippocampal neurogenesis (AHN), the lifelong birth of new neurons in the dentate gyrus, supports learning, memory, and mood. Microglia, the brain's immune cells, regulate AHN, and disruptions in AHN and microgliosis are linked to both depression and neurodegenerative diseases. Psychedelics like psilocybin, a serotonergic agonist with rapid antidepressant effects, may promote neuroplasticity and modulate microglial function. This narrative review examines evidence that psilocybin could affect AHN and microglia, potentially altering the progression from major depression to dementia in at-risk individuals.

Online mindfulness meditation for mild cognitive impairment and mild dementia: A feasibility study protocol.

PloS one January 1, 2025 Jiuhong You, Zunera Khan, Reena Swaroop et al.

An eight-week, online-delivered mindfulness program is being tested for feasibility and acceptability in people over 60 with mild cognitive impairment or mild dementia in the UK. The study will recruit 32 participants who will attend weekly live online sessions led by an experienced teacher, plus daily home practice. Primary outcomes are feasibility and acceptability measured through participation records and interviews. Secondary outcomes include changes in cognition, mood, sleep, quality of life, mindfulness, and resilience. Online delivery could reduce travel burdens and costs, and the study aims to provide evidence supporting remote interventions for this population.